|August 17, 2022
|Single Dose 186RNL for Leptomeningeal Metastases: Multicenter Phase 1/2a Study to Determine MTD/MFD, Safety & Efficacy, Leading to Pivotal Registrational Trial
|Product Development Research
|Texas Company Product Development Awards
|PLUS Therapeutics, Inc.
|Principal Investigator/Program Director
|Breast, Lung and Bronchus, Skin
PLUS Therapeutics' Rhenium-186 NanoLiposome (186RNL) is a novel radiotherapeutic being developed to combat rare and difficult-to-treat cancers. Currently in clinical development for recurrent glioblastoma, 186RNL is safe and well-tolerated while delivering a radiation dose to the tumor that is up to 15 times higher than typically achievable with standard radiation therapy. PLUS now plans to develop 186RNL to treat leptomeningeal metastases (LM), a rare but typically fatal complication of advanced cancer affecting the fluid-lined structures surrounding the brain and spinal cord. LM affects over 110,000 people in the U.S. every year and, even with the best available care, is rapidly fatal with...